“If the genus claims come to an end, it will not be science that will ‘behind’, but instead the research that follows and invests in important life-saving human health innovations.” – Ashley Sloat
yesterday’s oral arguments amgen vs sanofi It has been eagerly awaited and watched by many in the patent community. Judges appeared skeptical that the Court of Appeals for the Federal Circuit’s (CAFC) decision would be such a departure from existing law, and that this particular case does not, on the facts, undermine the current legal test. I repeatedly questioned whether it could be solved by adopting. In oral arguments, Sanofi’s attorney, Paul Clement, acknowledged that the court’s upholding of the CAFC’s ruling may result in the inability to functionally assert the genus in this particular area of antibody science. However, “the claims of functional genera are terrible. I think they are delaying science.”
Commenting yesterday, Judge Paul Michelle said Clement’s speculation that the genus “delays science” is not what human health innovation policy needs right now. Below, several other stakeholders discuss possible outcomes of litigation based on the allegations. Most stakeholders agree that the court is unlikely to make any significant changes to the Federal Circuit’s approach.
Thomas Hedeman and Patrick Doyle,axe
Justices Thomas, Sotomayor, Jackson, and Gorsuch raised a number of issues in yesterday’s oral argument, much like the general skepticism that the Federal Circuit’s enabling case law is inconsistent with patent law. Looked.
Many questions were raised as to whether the controversy actually involved the Federal Circuit’s enablement standard, or simply applied to the specific facts of this case. Amgen and Sanofi set standards for ‘wrongful experimentation’ and wand It is more likely that courts will not change the current standards significantly.
If the court chooses to provide guidance on some aspect of the standard, it will reflect what Amgen called the Federal Circuit’s “cumulative effort” factor, the cumulative effort it takes a skilled craftsman to do. It can be about time and effort. every day Incarnation of the genus. Amgen asked the court to dismiss this element, arguing that the effort required to make the embodiment material to those skilled in the art should be considered. Sanofi believes that the joint effort to achieve all realizations will: should do it At least Judge Sotomayor seemed sympathetic.
Many of the questions concerned the facts of the case, such as the number of antibodies that could be included in the claims, the steps required to make them, and the time and effort involved in considering high-throughput technology. suggested in the discussion that remand may be appropriate if the dispute between the parties is factual.
William H. Milliken
Stern Kessler
Based on the judge’s questions, and perhaps more importantly, the supporters’ answers, it seems unlikely that the Supreme Court’s final decision will result in significant changes to enablement law. Both parties and the United States appear to agree on the following points: “Excessive experimentation” is the appropriate standard.eight wand Factors are useful guides in determining whether undue experimentation is required to practice the claimed invention. The full range of claims must be valid. Also, it is not necessary that one skilled in the art be able to cumulatively identify all embodiments within the claims without undue experimentation to enable the claims. Given the agreement on these principles, the courts are unlikely to interfere with any of them, so this post-judgment law will likely be very similar to current law. is not important. Whenever the Supreme Court provides guidance on one of the patentability requirements, it is of great importance to patent practitioners. However, the thrust of today’s discussion suggests that the basic structure of enablement legislation will generally remain intact, along with much of the existing precedent for it.
The express agreement between the parties and the Court was the 1988 wand This decision provides a good lens for analyzing enablement. This is a special pride for us at Sterne Kessler Goldstein & Fox. The company’s Jorge Goldstein successfully represented Wands in the appeal that led to its important decision.
Mark Remus
and Alexis White Crowell & Moring
Based on oral argument, the court appears likely to uphold the Federal Circuit’s decision. The judge repeatedly noted that there appeared to be little, if any, disagreement between Amgen, Sanofi, and the Federal Circuit regarding the appropriate legal test for validation. Specifically, when pressured by the courts, Amgen and Sanofi agreed on criteria for undue experimentation and the Wands factor for evaluating undue experimentation when these factors were properly applied. bottom. As Judge Cagan referred to Amgen’s defense attorneys, “Do you understand that the parties have all agreed on the appropriate legal test, and simply how that test applies in this case?” Are you just arguing?” Judge Gorsuch asked Sanofi’s attorneys, “If we agree to the law, what’s left in this court?” Sanofi’s attorneys said “nothing,” but the court provoked laughter from the attendees by suggesting that the appeal be dismissed as wrongfully granted. DIG cannot be ruled out, but it seems unlikely. Indeed, Judge Sotomayor then asked the government what the court could say about what the Federal Circuit had not yet said if the court was unwilling to investigate the matter. Instead, it seems likely that the court will uphold the Court of Appeals for the Federal Circuit. In support of that affirmation, the court is likely to confirm that undue experimentation and the wand element are appropriate criteria for validation. It is likely to dismiss Amgen’s claim that it improperly treated the amount of effort required to create it as conclusive of the issue of enablement. Amgen’s “cumulative effort” argument appears to have gained no support in court, and Judge Sotomayor, in sharp questioning of Amgen’s attorneys, said the Federal Circuit found the effort element decisive. He said he never said it was a thing. amount of effort.
and
Leu Schwerin, Saul Ewing
Yesterday’s discussion was wide-ranging and had a surprising amount of humor. The court pointed to the vast number of defense counsel briefs that the case had attracted, and joked that he had many friends.
One of Amgen’s most difficult questions was identifying where the controversy lies. Petitioner’s attorneys appeared to agree when asked whether the parties agreed on the law underlying enablement and disagreed on its application to the facts at hand. This effort to identify the parties’ disputes suggests that the court’s decision does not overhaul the enablement law, but rather provides some adjustments.
These arguments provided the court with an opportunity to revisit some of the time-honored validation precedents. Consolidated Electric Light Co. vs. McKeesport Light Co.., 159 US 465 (1895) (“incandescent lamp patent”). They also gave the court an opportunity to join the Federal Circuit’s decision. In Le Ones, its eight-factor test is the current standard for validation (under the Federal Circuit).court approval wand— or criticism of it — can be clarified.
One of the most interesting discussions concerned how the enablement doctrine sits alongside other doctrines of patent law. The petitioner, the defendant and his government all three gave interesting views on this.
The Attorney General noted that an infringer’s attempt to copy a patented invention but avoid liability by making minor modifications is best addressed by the doctrine of equivalents. The Supreme Court confirmed the viability of this doctrine some 25 years ago. Warner-Jenkinson Co. v. Hilton Davis Chemical Co.., 520 US 17 (1997). When asked whether this would provide the same scope of protection as a functional claim, the government tactfully conceded this point and retreated to the point that the scope of patent claims should be commensurate with the disclosure.
Petitioner Amgen discussed enablement under § 112(a) in relation to ambiguity under § 112(b). It appeared to argue that this was actually a claim clarity dispute (under the latter) that was disguised as under the former.Finally, Sanofi defendant innumerableargued that Amgen’s claims were effectively alleging natural phenomena, and that they were stuck as a result. innumerable. Association for Molecular Pathology v. Myriad Genetics, Inc.., 569 US 576 (2013).
Dr. Ashley Sloat
, Aurora Consulting LLC
Unfortunately, we find ourselves in a very decidedly hostile world, ruled and judged by a tragic cocktail of ignorance and over-influence.
If the genus claim comes to an end, it will not be science that will “behind”, but instead the investment and subsequent research in critical life-saving human health innovations that we will all miss. .
Wiping out genus claims creates a massive runway to drug piracy through easy design evasion. Antibody science has existed for nearly half a century. Without the genus claim, we could easily make another antibody that falls outside the narrower set of species claims that would only target drugs. Think of it this way. When an animal is immunized, a subset of the animal’s B cells produce antibodies specific to the immunized antigen. Every animal that is immunized provides a different set of her B cells based on species, exposure history, type of adjuvant used, etc. Any of these B cells can be isolated and the antibodies they produce can be therapeutic. Claiming a realistically practical number of species leaves a gap in the possibilities for easy engineering with all other B cells producing antibodies that also bind antigen.
